Evidence map›Paper›PMID 40278298›Full record

ArticleMarine drugs2025

Exploring the In Vivo Fate of β-1, 3/1, 6-Glucan Using Quantitative Tandem Mass Spectrometry Based on a Structure-Specific Fragment.

Shuying Xu, Jiale Hao, Chunyan Ye, Xintong Li, Pengcheng Gao, Ni Song, Chanjuan Liu, Youjing Lv, Guangli Yu, Guoyun Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuying XuKey Laboratory of Marine Drugs (Ministry of Education), Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Jiale HaoKey Laboratory of Marine Drugs (Ministry of Education), Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Chunyan YeKey Laboratory of Marine Drugs (Ministry of Education), Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Xintong LiKey Laboratory of Marine Drugs (Ministry of Education), Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Pengcheng GaoKey Laboratory of Marine Drugs (Ministry of Education), Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Ni SongKey Laboratory of Marine Drugs (Ministry of Education), Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Chanjuan LiuKey Laboratory of Marine Drugs (Ministry of Education), Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Youjing LvKey Laboratory of Marine Drugs (Ministry of Education), Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
Guangli YuKey Laboratory of Marine Drugs (Ministry of Education), Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.ORCID 0000-0002-6372-9750
Guoyun LiKey Laboratory of Marine Drugs (Ministry of Education), Shandong Key Laboratory of Glycoscience and Glycotherapeutics, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.

Funding

Fundamental Research Funds for the Central Universities 202441010Key Scientific and Technological Projects of Shandong Province 2021KJ012Key Scientific and Technological Projects of Shandong Province 2021ZDSYS22National Natural Science Foundation of China 32371338National Natural Science Foundation of China 81991522Qingdao Marine Science and Technology Center 2022QNLM030003-4Taishan Scholar Project TSPD20210304Taishan Scholar Project TSPD202408073
6 · The paper itself

Abstract

β-glucan, a promising drug candidate for immuno-antitumor therapy, holds tremendous potential for clinical applications. However, the absence of highly sensitive quantitative methods for polysaccharides, attributed to their complicated chemical structures and susceptibility to endogenous interference, has posed significant challenges for their clinical development. Here, we report a highly sensitive and reliable analytical strategy for quantifying β-1, 3/1, 6-glucan derived from

Indexed as

beta-GlucansAnimalsChromatography, High Pressure LiquidHumansMiceTandem Mass Spectrometrybeta-Glucansin vivo fatemethod validationoligosaccharide-markerUPLC-MS/MSβ-1, 3/1, 6-glucan

Identifiers

PMID40278298
PMCPMC12028845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.